title: Drug nanoparticle formulation using ascorbic Acid derivatives.
abstract: Drug nanoparticle formulation using ascorbic acid derivatives and its therapeutic uses have recently been introduced. Hydrophilic ascorbic acid derivatives such as ascorbyl glycoside have been used not only as antioxidants but also as food and pharmaceutical excipients. In addition to drug solubilization, drug nanoparticle formation was observed using ascorbyl glycoside. Hydrophobic ascorbic acid derivatives such as ascorbyl mono- and di-n-alkyl fatty acid derivatives are used either as drugs or carrier components. Ascorbyl n-alkyl fatty acid derivatives have been formulated as antioxidants or anticancer drugs for nanoparticle formulations such as micelles, microemulsions, and liposomes. ASC-P vesicles called aspasomes are submicron-sized particles that can encapsulate hydrophilic drugs. Several transdermal and injectable formulations of ascorbyl n-alkyl fatty acid derivatives were used, including ascorbyl palmitate.
authors: Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba 260-8675, Japan.
authors: Kunikazu
authors: K
authors: Moribe
authors: Waree
authors: W
authors: Limwikrant
authors: Kenjirou
authors: K
authors: Higashi
authors: Keiji
authors: K
authors: Yamamoto
references: Pharmazie. 2005 Oct;60(10):751-5
references: 16259122
references: Int J Pharm. 2007 Dec 10;345(1-2):26-34
references: 17964094
references: Pharm Res. 2008 Nov;25(11):2567-72
references: 18618230
references: Pharmazie. 2005 Aug;60(8):577-82
references: 16124399
references: Int J Pharm. 2007 Feb 22;331(1):38-45
references: 17055675
references: Int J Pharm. 2004 Mar 1;271(1-2):95-113
references: 15129977
references: Int J Pharm. 2005 Mar 3;291(1-2):21-9
references: 15707728
references: Colloids Surf B Biointerfaces. 2010 Mar 1;76(1):292-7
references: 20004558
references: Int J Pharm. 2007 Aug 1;340(1-2):198-206
references: 17482778
references: Pharm Res. 2011 Feb;28(2):301-8
references: 20730558
references: J Med Chem. 2002 Jan 17;45(2):462-8
references: 11784150
references: J Pharm Sci. 2009 Dec;98(12):4796-807
references: 19367621
references: Int J Pharm. 2008 Apr 16;354(1-2):227-34
references: 18242898
references: Int J Pharm. 2010 Mar 15;387(1-2):236-43
references: 20005934
references: Eur J Pharm Sci. 2003 Jul;19(4):181-9
references: 12885382
references: J Pharm Sci. 2002 Aug;91(8):1810-6
references: 12115808
references: Biol Pharm Bull. 2006 Apr;29(4):766-71
references: 16595915
references: Int J Pharm. 2001 Jul 17;222(2):271-9
references: 11427357
references: Yakugaku Zasshi. 1966 May;86(5):376-83
references: 6011001
references: J Microencapsul. 2008 Mar;25(2):111-20
references: 18246489
references: Pharm Res. 1998 Nov;15(11):1737-42
references: 9833996
references: J Control Release. 2006 Jul 20;113(3):189-207
references: 16790290
references: Biol Pharm Bull. 2007 Feb;30(2):393-6
references: 17268089
references: J Microencapsul. 2010 May;27(3):218-25
references: 19566395
references: Chem Pharm Bull (Tokyo). 2003 Jan;51(1):40-5
references: 12520126
references: Appl Microbiol Biotechnol. 2009 Jan;81(6):1013-22
references: 19030854
references: Transplant Proc. 2000 Mar;32(2):313-7
references: 10715427
references: Int J Pharm. 2007 Feb 7;330(1-2):54-60
references: 17071026
references: Biochim Biophys Acta. 1990 Jul 20;1035(1):44-50
references: 2200520